Cachet Pharmaceutical released its 2026 interim report, with total operating revenue of 8.278 billion yuan, down 14.65% year-on-year; net profit attributable to the parent company was 86.7582 million yuan, down 19.12% year-on-year. Net cash inflow from operating activities was 437 million yuan, down 3.49% year-on-year. The company's asset-liability ratio was 48.66%, gross margin was 5.90%, ROE was 1.95%, and diluted earnings per share was 0.30 yuan. The number of shareholders was 24,200, and the top ten shareholders held 42.21% of the total share capital.
Cachet Pharmaceutical Co LtdNet profit down 19.12% year-on-year in interim report
